Summit Securities Group
BMRN icon

Summit Securities Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Summit Securities Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$59.9K Buy
+999
New +$62.9K 0.01% 535
2019
Q3 		– Sell
-6,000
Closed -$514K – 339
2019
Q2 		$514K Buy
+6,000
New +$513K 0.06% 205

Other funds holding BMRN

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
ARGA Investment Management
ARGA Investment Management Stamford, Connecticut $3.94B AUM 28.9% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return
Fort Washington Investment Advisors
Fort Washington Investment Advisors Cincinnati, Ohio $19.7B AUM 20.11% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Summit Securities Group's BMRN Position: Q3 2026 in Review

Summit Securities Group opened a new position in BioMarin Pharmaceuticals (BMRN) in Q3 2026: 999 shares worth $59.9K. The stake represents 0.01% of the portfolio and ranks #535 among its holdings. This is a return to the name: Summit Securities Group previously reported a position in BMRN as recently as Q2 2019.

Summit Securities Group first reported a position in BMRN in Q2 2019 and has held it in 2 quarters since. The position peaked at $514K in Q2 2019. 271 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

  • Summit Securities Group held 999 shares of BioMarin Pharmaceuticals worth $59.9K as of Q3 2026.
  • BioMarin Pharmaceuticals was a new Summit Securities Group position in Q3 2026.
  • BioMarin Pharmaceuticals made up 0.01% of Summit Securities Group's portfolio in Q3 2026, its #535 holding.
  • Summit Securities Group first reported a position in BioMarin Pharmaceuticals in Q2 2019 and has held it in 2 quarters since.
  • Summit Securities Group's BioMarin Pharmaceuticals position peaked at $514K in Q2 2019.
  • 271 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on Summit Securities Group's 13F filing for Q3 2026, filed 5 Nov 2026.